Our Team

Our Leadership Team

RONALD ANDREWS

PRESIDENT & CHIEF EXECUTIVE OFFICER

Ronnie Andrews  

Ronnie Andrews joined OncoCyte as Chief Executive Officer in July 2019. Prior to joining OncoCyte, Ronnie was the founder and principal of the Bethesda Group LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms into the marketplace. Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. In this role, Ronnie oversaw the integration of Life Technologies’ genetic platforms, including Life’s chip-based Next Generation Sequencing Technology, Ion Torrent. Prior to this Ronnie held a number of other high-profile executive roles including President of the Medical Sciences Venture within the Life Technologies Corporation, and he served as Chief Executive Officer of Clarient, a public company on the NASDAQ which was sold to General Electric Healthcare in December 2010. Ronnie is a passionate ambassador for the need for democratization of information into community-based environments to better manage deadly diseases like cancer, as well as control healthcare costs by keeping the patient and treatment close to home. He speaks regularly to industry groups and was selected as the Regional Winner for Ernst & Young’s Entrepreneur of the Year in 2011.

 

MITCH LEVINE

CHIEF FINANCIAL OFFICER

Mitch Levine  

Mitch Levine joined OncoCyte as Chief Financial Officer in November 2017. Prior to joining OncoCyte, Mr. Levine was the Managing Partner of Kirby Cove Capital Advisors, which provides consulting services to international life sciences investment funds regarding collaboration and investment in US-based life sciences companies. In 2002, Mr. Levine founded Enable Capital Management and grew the firm into one of the largest and most respected brands globally in alternative finance. Its flagship fund, Enable Growth Partners, provided growth capital to more than 500 private and publicly traded companies, catalyzing transformative corporate innovation, job growth, and economic expansion in technology, life sciences, consumer products, and energy. Prior to founding Enable, Mr. Levine was a founding member of The Shemano Group, a leading San Francisco-based investment bank that focused on the capital needs of growth companies. He has also worked at Bear Stearns and Lehman Brothers. Mr. Levine received his BA from the University of California, Davis.

AL PARKER

CHIEF OPERATING OFFICER

 

Al Parker joined OncoCyte as Chief Operating Officer in August 2018. Mr. Parker is an accomplished business and legal executive with over 25 years of broad domestic and international life sciences experience, having served in executive leadership roles in leading pharmaceutical, biotech, and healthcare companies. With a background in strategic planning, business development and operations, Mr. Parker’s prior roles include Executive Vice President, General Counsel and Corporate Secretary for Sunovion Pharmaceuticals, Senior Vice President and Global Chief Counsel for Wyeth Pharmaceuticals, and Managing Shareholder at GC Legal Advisors, where he also served in interim chief legal and compliance officer and other operating roles at a number of early stage biotech, pharma, and other healthcare related companies. Committed to strong corporate governance, Mr. Parker has been recognized as a Board Governance Fellow by the National Association of Corporate Directors. Mr. Parker earned his Juris Doctor from the University of Pennsylvania Law School, and his undergraduate degree in Economics from Penn State University.

 

LYNDAL HESTERBERG, PH.D.

CHIEF SCIENTIFIC OFFICER

Lyndal Hesterberg  

Lyndal Hesterberg Ph.D., joined OncoCyte as a consultant in 2015 and was named Vice President of Development in February of 2016. Dr. Hesterberg has worked as an industry consultant to medical and biotech companies providing counsel on clinical trial design, product development and corporate strategy. Previously, he was the CTO at Crescendo Biosciences until 2012 where he was responsible for clinical trial, laboratory operations, manufacturing and quality systems and helped bring to market Vectra DA. Before that, he was the president and CEO of Barofold, Inc., where he led the Company from product conception through its clinical stage. He also recruited a senior leadership team that developed a pipeline of proprietary drug candidates. Dr. Hesterberg also has been a Director of Research, EVP of Scientific affairs and Manager of Diagnostic Product Development. He received his Ph.D. in biochemistry from the University of St. Louis and a Bachelor of Sciences from the University of Illinois.

 

Padma Sundar

Senior Vice President, Marketing and Market Access

Ms. Sundar has an extensive experience in launching oncology tests for global diagnostics companies, helping them achieve market leadership positions. Prior to joining OncoCyte, Ms. Sundar served as Vice President of Strategy and Market Access at CellMax Life, where she launched the first blood test for preventative colon cancer screening. Prior to CellMax, she was a Director of Marketing at Guardant Health where she drove a 75% increase in test volume and adoption by U.S. oncologists. As a Senior Director at Roche Sequencing she launched the first next-generation sequencing (NGS) liquid biopsy kit for cancer recurrence monitoring. She was also Senior Director for the oncology portfolio at Affymetrix where she brought the first whole genome microarray kits “OncoScan” and “CytoScan” for solid and liquid tumor profiling to 50 leading academic and reference labs worldwide. Ms. Sundar began her career at McKinsey and Company, and received her M.B.A. and M.P.H. from the University of California, Berkeley, and her B.A. in Chemistry from the University of Delhi.

 

Dr. Kim Dickinson

Vice President, Clinical Operations

Dr. Dickinson has over two decades of industry expertise in overseeing global clinical trials and diagnostic testing, with an emphasis on anatomic, clinical, and digital pathology. Prior to joining OncoCyte, Dr. Dickinson served as Vice President of R&D and Chief Pathologist at BioCare Medical where she led a team responsible for the R&D and testing of antibody optimizations to support the launch and release of a new immunohistochemistry instrument. Prior to BioCare, she was a Vice President of Clinical Operations at Roche Tissue Diagnostics where she provided strategic operational leadership supporting the coordination and execution of more than 100 companion diagnostic, in vitro diagnostic clinical trials. Previously, at Laboratory Corporation of America, she was Medical Director for the Clinical Trials Division where she directed daily operations across five global anatomic pathology lab testing sites, as well as Medical Director for Esoteric Testing where she led a team of pathologists and operations staff. She received her M.D. from Hahnehmann University, her M.B.A. and M.P.H. from the University of California, Irvine, and her B.Sc. in Pharmacy from the University of Pittsburgh.

Our Medical Advisory Committee

THOMAS BAUER, MD

Thomas Bauer  

Dr. Bauer graduated from Jefferson Medical College and pursued his training in general surgery, research and cardiothoracic surgery at Thomas Jefferson university Hospital.  He served as the Chief of Thoracic Surgery at the Helen F Graham Cancer Center at Christiana Care Health System.  He currently serves at the Chief of Thoracic Surgery at Jersey Shore University Hospital and is the Medical Director of Thoracic Oncology at Meridian Health in the Hackensack Meridian Health System. Dr. Bauer has lead numerous clinical trials and has partnered with industry through device and pharmaceutical investigative trials for many years.  He has authored over 100 manuscripts, chapter, abstracts and presentations related to thoracic surgery.  He has a special interest in lung cancer screening research and clinical trials.  His clinical expertise is in robotic minimally invasive thoracic surgery for the treatment of lung cancer, first rib resections, esophageal cancer, benign foregut surgery and diaphragmatic pacing and reconstruction.

 

D. KYLE HOGARTH, MD, FCCP

KYLE HOGARTH  

Dr. Hogarth is Associate Professor of Medicine in the Section of Pulmonary and Critical Care Medicine at The University of Chicago. He is the Director of Bronchoscopy and is heavily involved in the field of interventional bronchoscopy with numerous publications. Dr. Hogarth received his medical degree at Case Western Reserve University School of Medicine in Cleveland, Ohio. He then completed a residency in Internal Medicine and a fellowship in Pulmonary and Critical Care at The University of Chicago. He has been published in the New England Journal of Medicine, Chest, and many other journals. He serves on the editorial board of CHEST, where he is the section editor for the podcast section.

 

EDWARD F. PATZ JR., MD

Edward F. Patz  

Dr. Patz is the James and Alice Chen Professor of Radiology and a Professor in Pharmacology and Cancer Biology at Duke University Medical Center. He began his training in High Energy Physics at Harvard University, received his MD from the University of Maryland, completed his residency and thoracic imaging fellowship at the Brigham and Women’s Hospital and Harvard Medical School, and then was appointed to the faculty in the Department of Radiology at the Brigham, Harvard Medical School, and the Dana Farber Cancer Institute. In 1991, he was recruited to the Thoracic Imaging section in the Department of Radiology at Duke. Dr. Patz is a clinician–scientist, with projects that focus on early lung cancer detection, molecular diagnostics, and novel therapeutic strategies. He has participated in numerous clinical trials including the National Lung Screening Trial (NLST), and for over 20 years has been the principal investigator of a basic science laboratory exploring lung cancer biology.

 

ANIL VACHANI, MD

Anil Vachani  

Dr. Vachani received his medical degree from the University of California, San Francisco in 1996, after which he completed internal medicine and pulmonary/critical care training at the University of Pennsylvania. He also holds a Masters in Clinical Epidemiology from the University of Pennsylvania. He is currently an Associate Professor of Medicine in the Pulmonary and Critical Care Division at the University of Pennsylvania in Philadelphia, PA, where he serves as Director of the Lung Nodule Program, Co-Director of the Lung Cancer Screening Program, and Director of Bronchoscopy at the Philadelphia VA Medical Center. He serves on various committees for the American Thoracic Society and is the Vice-Chair of the Thoracic Oncology Network of the American College of Chest Physicians. Dr. Vachani’s research is focused on the discovery and validation of early detection and treatment prediction biomarkers for lung cancer and mesothelioma. Additional areas of research include studies on the measurement of biomarkers from circulating tumor cells and circulating free DNA, Finally, he is conducting studies on population level uptake of genomic and genetic technologies for treatment decisions in lung cancer using cancer registry and claims data.

 

Our Board of Directors

CAVAN REDMOND

Chairman of the Board

Cavan Redmond joined the Board of Directors in September of 2015.  Mr. Redmond is a seasoned healthcare strategist, who has held a number of global leadership positions.  He currently is a partner at Zarsy, LLC.  His global leadership roles include: CEO of WebMD Health Corp., where he oversaw cost rationalizations and streamlined operations to position the company for growth; Senior Vice President and Group President, Pfizer Diversified Businesses.  The Diversified Business included Animal Health, Consumer Healthcare, Capsugel and Nutrition. While at Pfizer he also became the head of Corporate Strategy. While at Wyeth he was the first EVP and General Manager Wyeth Biopharma and President of Wyeth Consumer Healthcare.  He is currently a member of  the Board of Directors for the Arthritis Foundation, where he has served since 2014.   Mr. Redmond holds a MAS degree from Johns Hopkins University and a  BA from the University of Maryland at College Park. He was a 2012 recipient of The Johns Hopkins University Distinguished Alumnus Award.

 

RONALD ANDREWS, JR.

CHIEF EXECUTIVE OFFICER

Ronnie Andrews joined OncoCyte as Chief Executive Officer in July 2019. Prior to joining OncoCyte, Ronnie was the founder and principal of the Bethesda Group LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms into the marketplace. Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. In this role, Ronnie oversaw the integration of Life Technologies’ genetic platforms, including Life’s chip-based Next Generation Sequencing Technology, Ion Torrent. Prior to this Ronnie held a number of other high-profile executive roles including President of the Medical Sciences Venture within the Life Technologies Corporation, and he served as Chief Executive Officer of Clarient, a public company on the NASDAQ which was sold to General Electric Healthcare in December 2010. Ronnie is a passionate ambassador for the need for democratization of information into community-based environments to better manage deadly diseases like cancer, as well as control healthcare costs by keeping the patient and treatment close to home. He speaks regularly to industry groups and was selected as the Regional Winner for Ernst & Young’s Entrepreneur of the Year in 2011.

 

ANDY ARNO

Andy Arno was appointed as a member of the Board of Directors in June 2015. He is currently Vice Chairman/Partner of The Special Equities Group “SEG,” a small-cap capital markets group. He was previously Managing Director of Emerging Growth Equities, an investment bank, and Vice President of Sabr, Inc., as well as President of LOMUSA Limited, an investment banking firm. From 2009 to 2012, Andy served as Vice Chairman and Chief Marketing Officer of Unterberg Capital, LLC, an investment advisory firm that he co-founded. He also served as Vice Chairman and Head of Equity Capital Markets of Merriman Capital LLC, an investment banking firm, and served on the board of its parent company, Merriman Holdings, Inc. Mr. Arno currently serves on the Boards of Asterias Biotherapeutics, Comhear, and Smith Micro Software, Inc. He is a graduate of George Washington University.

 

Melinda Griffith

Melinda Griffith was appointed as a member of the Board of Directors in July 2019. She is chief legal counsel and the vice president of Strategic Alliance Management at the Parker Institute for Cancer Immunotherapy. She has extensive experience leading the business development, licensing, legal and compliance activities of diagnostic, device and pharmaceutical companies. She began her biotech career at Cetus Corporation, and lead the PCR licensing programs (300+ licensees, $100+ million annual royalty revenue) as head of business development, law and licensing for Roche’s molecular diagnostic business for almost a decade. Prior to these positions, Ms. Griffith held a number of executive roles at public and private biotech companies, including GE Healthcare’s In Vitro Cancer Diagnostics business (Clarient Cancer Laboratories), Genelabs Technologies, CardioDx, Tethys BioSciences, and Axys Pharmaceuticals.  Melinda holds a JD from the University of California, Hastings College of Law, and a BS from the University of California, Berkeley.

 

ALFRED D. KINGSLEY

Alfred D. Kingsley joined the Board of Directors in 2009 and was previously Chairman of the Board. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt Corp. served as our financial advisor from 1998 until June 30, 2009. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a BS degree in economics from the Wharton School of the University of Pennsylvania, and a J.D. degree and LLM in taxation from New York University Law School.

 

ANDREW J. LAST

Andrew J. Last joined the Board of Directors in December 2015. In January of 2018, Dr. Last was appointed as Chief Commercial Officer at Berkeley Lights. Previously, he served as Chief Operating Officer of Intrexon Corporation. From 2010 to 2016, Dr. Last was Executive Vice President and Chief Operating Officer of Affymetrix. Before joining Affymetrix, Dr. Last served as Vice President, Global and Strategic Marketing of BD Biosciences and as General Manager of Pharmingen from 2004 to 2010. From 2002 to 2004, Dr. Last held management positions at Applied Biosystems, Inc., including as Vice President and General Manager from 2003-2004 and Vice President of Marking 2002-2003. Earlier in his career, he served in a variety of management positions at other companies, including Incyte Genomics and Monsanto. Dr. Last holds Ph. D. and MS degrees with specialization in Agrochemical Chemicals and Bio-Aeronautics, respectively, from Cranfield University, and a BS degree in Biological Sciences from the University of Leicester in the United Kingdom.

 

ADI MOHANTY

Adi Mohanty joined the Board of Directors in April 2015. Mr. Mohanty currently has served as BioTime’s, Chief Operating Officer since December 2014 and Co-Chief Executive Officer since October 2015. He was formerly with Shire plc, a biotechnology company focused on research, development and commercialization of novel biological products for rare diseases, where he served in a number of executive positions, including as President/Head Regenerative Medicine from 2013 to 2014, as Senior Vice President, Business and Technical Operations from 2012 to 2013, and as Global Franchise Head MPS from 2010 to 2012. Mr. Mohanty served as Vice President at Transkaryotic Therapies from 2002 to 2005 when it was acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty held a number of management positions in the Bioscience Division of Baxter Healthcare Corporation. Mr. Mohanty received an MBA degree from Saint Mary’s College and has an MS and BS in Chemical Engineering.